# US 2026/0097004 A1 · Pharmaceutical composition for treating mast cell-mediated inflammatory diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097004 A1
- Document ID: US20260097004A1
- Status: Published application
- Kind: A1
- Application number: 19/120,757
- Filed: 2022-10-12
- Published: 2026-04-09
- Earliest claimed: 2022-10-12
- Inventors: Lei CHU; Ethan A. LERNER; Vemuri B. REDDY; Yuping RAN
- Web page: https://patentgrep.com/patent/US20260097004A1

## CPC

- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to use of Atovaquone for treating and preventing acute and chronic inflammatory diseases in a mammal. The acute and chronic inflammatory diseases comprise mast cell-mediated inflammatory diseases.

## Claims

### Claim 1

A pharmaceutical composition for treating or preventing mast cell-mediated inflammatory diseases, wherein the pharmaceutical composition comprises an active ingredient Atovaquone.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the concentration of the active ingredient Atovaquone is 0.0001-100 mg/ml.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition further comprises a second active ingredient.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier.

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is an emulsified paste, an emulsion, a cream, a solution, a patch, a gel, an aerosol, a tablet, a granule, or an injection.

### Claim 6

Use of Atovaquone in a pharmaceutical composition for treating or preventing mast cell-mediated inflammatory diseases.

### Claim 7 (depends on 6)

The use according to claim 6, wherein the inflammatory diseases comprise allergies and atopic disorders, mast cell activation syndrome (MCAS), physical and chemical urticaria, idiopathic urticaria, Crohn's disease, inflammatory bowel diseases, dermatitis and contact dermatitis, arthritis and rheumatoid arthritis, skin, tissue, or systemic reactions to stinging or other allergic or quasi-allergic stimuli, canine mastocytosis, and allergies and inflammations in cattle and pigs.

### Claim 8 (depends on 7)

The use according to claim 7, wherein the inflammatory diseases further comprise skin eczema, dermatitis, atopic dermatitis, contact dermatitis, neurodermatitis and urticaria in adults, children or infants.

### Claim 9 (depends on 6)

The use according to claim 6, wherein the pharmaceutical composition is administrated systemically or topically.
